In response, Dave presents a study to be discussed at the 2024 American Society of Hematology (ASH) Annual Meeting and ...

Zanidatamab is now a category 2A treatment for HER2-positive biliary tract cancer in the NCCN guidelines, following its FDA ...

If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of ...

Samer A. Al’Hadidi, MD, discusses the importance of personalized medicine in patients with multiple myeloma.

Nobel Prize in Chemistry highlights AI-driven breakthroughs in computational protein design and structure prediction. Tools ...

In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection ...

Akriti Jain, MD, discusses what she is most looking forward to seeing presented at the upcoming 2024 American Society of Hematology Annual Meeting and Exposition.

Panelist discusses how the RRMM treatment landscape has evolved significantly, with BiTEs emerging as a promising approach. BCMA-targeted BiTEs showed efficacy, while GPRC5D-targeting agents like ...

CRB-701 has gained FDA fast track status for the treatment of adult patients with relapsed/refractory metastatic cervical ...

Patients with multiple myeloma face a complex, decades-long treatment journey involving care coordination, insurance ...

The FDA has accepted an sBLA for glofitamab plus gemcitabine and oxaliplatin in relapsed/refractory diffuse large B-cell ...

Lung cancer innovations are not only extending lives but also enhancing the quality of life for patients, offering renewed ...